What is Palvella Therapeutics's loss on debt extinguishment?

Palvella Therapeutics (PVLA) reported loss on debt extinguishment of $0 in Q4 2024.

How has Palvella Therapeutics's loss on debt extinguishment changed year-over-year?

Palvella Therapeutics's loss on debt extinguishment decreased by 100.0% year-over-year, from $5.77M to $0.

Non-cash loss from retiring debt before maturity, added back in operating cash flow since the cash impact is in financing.

BridgeBio PharmaBBIO

$0+100%

Roivant SciencesROIV

$0+100%

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Market cap$1.86B+468%

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.

The official record: Palvella Therapeutics’s 10-K, filed March 31, 2025, on SEC EDGAR. View the filing →

What is Palvella Therapeutics's loss on debt extinguishment?: Palvella Therapeutics (PVLA) reported loss on debt extinguishment of $0 in Q4 2024.
How has Palvella Therapeutics's loss on debt extinguishment changed year-over-year?: Palvella Therapeutics's loss on debt extinguishment decreased by 100.0% year-over-year, from $5.77M to $0.
What does loss on debt extinguishment mean?: Non-cash loss from retiring debt before maturity, added back in operating cash flow since the cash impact is in financing.